FDA+ roundup: Final guidance on the fastest oncology drug approvals; Remote inspections fail to take off
The FDA on Tuesday finalized guidance from July 2022 on the speedy cancer drug reviews that, for the last six years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
